SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study
Ryan Allway August 2nd, 2021 Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ — SciSparc Ltd. (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )